Absci

ABSI

Market cap $454M

Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the upcoming 44th Annual J.P.

Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo

Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease

Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.

Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase 2 for endometriosis KOL seminar scheduled for December 11 to discuss new human ex vivo data, clinical trial design, and market opportunity in AGA VANCOUVER, Wash. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in the Phase 1/2a HEADLINE study evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci's generative AI platform.

Artificial intelligence (AI) will reshape industries for decades, making early positioning in focused AI players critical. Smaller AI companies often offer more upside than megacaps that have already priced in the boom.

Absci Corporation ( ABSI ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Sean McClain - Founder, CEO, President & Director Presentation Operator It's my pleasure to now introduce Sean McClain, CEO; and Zach Jonasson, CFO of Absci Corporation. Just a reminder, there will be a 20-minutes presentation following with 5 minutes Q&A.

Absci Corporation ( ABSI ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Andreas Busch - Chief Innovation Officer & Member of Scientific Advisory Board Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Brendan Smith - TD Cowen, Research Division Sean Laaman - Morgan Stanley, Research Division Gil Blum - Needham & Company, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Presentation Operator Thank you for standing by. My name is Rochelle, and I will be your operator today.